Azadirachta indica ethanolic extract protects neurons from apoptosis and mitigates brain swelling in experimental cerebral malaria

Selma Bedri1, Eltahir A Khalil1, Sami A Khalid2, Mohammad A Alzohairy3, Abdilmarouf Mohieldein3, Yousef H Aldebas4, Paul Faustin Seke Etet5 and Mohammed Farahna5*

Abstract

Background: Cerebral malaria is a rapidly developing encephalopathy caused by the apicomplexan parasite Plasmodium falciparum. Drugs currently in use are associated with poor outcome in an increasing number of cases and new drugs are urgently needed. The potential of the medicinal plant Azadirachta indica (Neem) for the treatment of experimental cerebral malaria was evaluated in mice.

Methods: Experimental cerebral malaria was induced in mice by infection with Plasmodium berghei ANKA. Infected mice were administered with Azadirachta indica ethanolic extract at doses of 300, 500, or 1000 mg/kg intraperitoneally (i.p.) in experimental groups, or with the anti-malarial drugs chloroquine (12 mg/kg, i.p.) or artemether (1.6 mg/kg, i.p.), in the positive control groups. Treatment was initiated at the onset of signs of brain involvement and pursued for five days on a daily basis. Mice brains were dissected out and processed for the study of the effects of the extract on pyramidal cells’ fate and on markers of neuroinflammation and apoptosis, in the medial temporal lobe.

Results: Azadirachta indica ethanolic extract mitigated neuroinflammation, decreased the severity of brain oedema, and protected pyramidal neurons from apoptosis, particularly at the highest dose used, comparable to chloroquine and artemether.

Conclusions: The present findings suggest that Azadirachta indica ethanolic extract has protective effects on neuronal populations in the inflamed central nervous system, and justify at least in part its use in African and Asian folk medicine and practices.

Keywords: Cerebral malaria, Azadirachta indica extract, Pyramidal neurons, Neuroinflammation, Brain oedema

Background

Cerebral malaria is a rapidly developing encephalopathy that represents the most severe neurological complication of infection with Plasmodium falciparum. Cerebral malaria mainly occurs in resource-poor tropical countries, and mostly affects children [1,2]. Surviving patients display neurologic and cognitive deficits, including consciousness impairment, cerebellar ataxia, seizures, and coma, making cerebral malaria a major cause of childhood neurodisability in endemic areas [3-6]. The pathogenesis of neuro-cognitive sequelae is poorly understood.

Experimental models of cerebral malaria have been providing new mechanistic insights that will help develop efficient neuro-protective interventions. The non-human pathogenic parasite Plasmodium berghei has been used to induce experimental cerebral malaria in mice that has some features comparable to the human disease [7-9]. Experimental evidence suggests that the vast array of pro-inflammatory molecules released by the host to fight the infection and alterations due to parasite sequestration in the microvessels cause leakage of plasma into the parenchyma resulting in brain oedema, and may contribute to the subsequent blood–brain
barrier breakdown [10,11]. Brain parenchyma infiltration by danger or pathogen-associated molecules would trigger a sustained detrimental neuroinflammatory response leading to the recruitment of circulating immune cells. The latter cells would induce death through cell-mediated apoptosis in sensible neuronal populations, by triggering pathways such as caspase 3 and Fas-Fas ligand [12-14]. Previous studies and reports have shown that such inflammation-triggered apoptosis can induce cerebellar ataxia when affecting Purkinje cells in the cerebellum [15-17]. Similarly, apoptosis affecting cortical neurons may explain many other neurologic deficits observed in experimental cerebral malaria, such as cognitive impairment or seizures [18-21]. Overall, these findings corroborate the alterations reported in humans [9,14,22,23]. New effective drugs are urgently needed for cerebral malaria treatment due to the development of parasite chemoresistance, and to improve current drugs’ poor treatment outcome [24-26].

**Azadirachta indica** is a plant commonly used in the African and Asian folk medicine and practices [27-31]. Anti-malarial effects of *A. indica* extracts have been demonstrated [32-36], as well as the neuro-protective effects on Purkinje cells of *P. berghei*-infected mice successfully mitigating cerebellum malaria [16]. The present study addresses the potential of *A. indica* extract for the protection of cortical and sub-cortical pyramidal neurons of *P. berghei*-infected mice, considering the implications for the treatment of cerebral malaria-associated cortical deficits.

**Methods**

**Experimental procedure**

Thirty five mice, divided into seven groups (five animals per group), were used in this study. These groups were: *i*) a disease control group made of untreated *P. berghei*-infected mice; *ii*) two positive control groups made of *P. berghei*-infected mice treated with the commercially available anti-malarial drugs chloroquine (12 mg/kg in distilled water, i.p.) and artemether (1.6 mg/kg in olive oil, i.p.); *iii*) three experimental groups made of *P. berghei*-infected mice treated with *A. indica* ethanolic extract at doses 300, 500, or 1000 mg/kg (i.p.); *iv*) and a group of uninfected healthy animals. Parasitaemia, body weight, core body temperature, and signs of brain involvement were monitored. Treatment was started when the number of parasitized red blood cells was >5% (severe malaria indicator) and was associated with signs of brain involvement. Treatment was pursued for five days on a daily basis. Mice either died spontaneously or were sacrificed by ether inhalation-induced deep anaesthesia once signs of disease terminal stage (hypothermia, ptosis, and convulsion) [37], were observed. Uninfected mice were sacrificed concomitantly with the last animals to check for disease terminal stage signs. For all animals, brains were dissected out and processed for histopathological analysis.

**Animals and infection**

Male Swiss albino mice (weighing 26.5 ± 3.0 g, aged 6 ± 1 week) were donated by Sudan National Health Laboratory (Khartoum, Sudan). Mice were maintained at a 12:12 light/dark cycle and were given ad libitum access to food (standard diet) and water. For infection, mice were administered (i.p.) with a load of 10 × 10⁶ parasitized red blood cells containing *P. berghei* ANKA. The parasitaemia was checked by blood smear Giemsa-staining. All procedures received approval from the Ethical Committee of the Institute of Endemic Diseases of the University of Khartoum and animals were handled according to institutional guidelines. *Plasmodium berghei* ANKA blood-stage cryoplastites were kindly donated by Dr. C.R. Pillai (National Institute of Malaria, New Delhi, India).

**Preparation of the extract**

Fresh leaves of *A. indica* were collected in Khartoum region, where they are commonly used in folk medicine to treat malaria [33], and shade-dried. Dry leaves were ground, and 1500 g of powder were macerated in 15 L of ethanol for three consecutive days at room temperature. A 1 mg/mL stock solution was obtained by filtration and boiling of the supernatant, and was stored at 4°C until use. Three doses of *A. indica*, i.e. 300, 500, and 1,000 mg/kg, were administered to the respective experimental groups once a day for five days. These regimens were chosen in accordance with previous pharmacological studies in malaria models [16,28].

**Pyramidal neuron density and brain oedema**

Brains dissected out were fixed in 10% neutral buffered formaldehyde, then paraffin-embedded and cut sagittally (section thickness: 5 μm). Sections were deparaffinized in xylene, rehydrated, and processed for haematoxylin-eosin (H&E) staining. The pyramidal neuron volumetric density, i.e. the proportion of brain subfield that is occupied by pyramidal neuronal cell bodies, was determined as described by Highley and colleagues [38]. Pyramidal neurons were counted on five consecutive sections, in the medial temporal lobe, using a light microscope with a fixed 1 cm grid eyepiece under 40× objective. Brain oedema was assessed by giving a severity score integrating histopathological parameters, such as the importance (how big) and frequency (how numerous) of fluid built up in the brain parenchyma, on the H&E stained sections [39,40].

**Immunohistochemistry**

The sections processed for immunohistochemical labeling were deparaffinized in xylene, rehydrated, and endogenous
peroxidase activity was extinguished. Sections were then pre-incubated in normal serum buffer solution (Diagnostic BioSystems, Serpentine, CA, USA), and incubated for 3 h in either rabbit anti-caspase-3, anti-FAS, anti-FAS ligand, anti-tumor necrosis factor (TNF), or anti-nitric oxide synthase (NOS) primary antibody buffer solution (dilution factor 1:40, Lica Biosystem Newcastle Ltd, UK), followed by a biotinylated secondary antibody and streptavidin-conjugated hors eradish peroxidase (Vision Biosystems Novocastra, Novocastra Laboratories Ltd., Newcastle, UK) prepared according to the kit instructions. The sections were incubated with 3,3′-diaminobenzidine hydrochloride (DAB) chromogen substrate (Vision Biosystems Novocastra) according to the manufacturer’s instructions, and counterstained with H&E. P value < .05 was considered significant. Thorough washes between steps were performed using immune wash buffer (Vision Biosystems Novocastra). Sections were dehydrated through a graded ethanol series, cleared in xylene, and covered with a thin glass coverslip. The fraction of pyramidal neurons expressing each of the studied markers, i.e. the markers of apoptosis caspase 3, Fas, and Fas ligand, and the markers of neuroinflammation-triggered apoptosis TNF and NOS, was determined using a light microscope under 40× objective.

**Statistical analysis**

Data obtained from infected treated or uninfected groups were compared to those obtained from the infected untreated group using one-way ANOVA followed by LSD.
test. Differences with a p value < .05 were considered statistically significant. All data were expressed as a percentage of the value obtained in the infected untreated group. Data are presented as mean ± SEM (n = 5).

Results

General observations

The early signs of disease started five days after infection in the majority of P. berghei-infected animals, i.e. in the disease control group and in animals treated with chloroquine, artemether, or one of the three doses of A. indica extract. Cerebral malaria signs appeared at day 6 ± 1 post-infection. The most recurrent ones were a ruffled fur, locomotor impairments, and sickness behavior (anorexia, cachexia, fever) associated with body weight loss. Animals treated with A. indica, chloroquine or artemether did not displayed fever (as evaluated by increases in core body temperature), and from dose 500 mg/kg of extract locomotor disturbances and body weight loss were improved. Parasitaemia was decreased in infected mice following treatment with chloroquine or artemether (from 6.1 ± 1.8% to 1.2 ± 0.4%, P < 0.05), but no significant change was observed in A. indica-treated animals, as previously reported [16].

Azadirachta indica extract did not protected infected mice from death, unlike chloroquine and artemether, although the highest doses slightly (not significantly) delayed death time. Infected untreated mice spontaneously died at day 9 ± 1 post-infection, A. indica-treated mice treated with the highest doses started to die at day 11, whereas no animal died in groups treated with chloroquine and artemether during the time of observation.
However, about all the survivors in groups treated with the extract were sacrificed two days after (day 13 post-infection) as terminal signs of cerebral malaria, i.e. hypothermia, ptosis, ataxia, and convulsion, were observed. All other animals, including those treated with chloroquine or artemether as well as uninfected ones were also sacrificed then.

**Extract effect on pyramidal neuron density**

The effect of *A. indica* on *P. berghei*-infected mice pyramidal neuron volumetric density is shown in Figure 1. The volumetric density of pyramidal neurons of mice treated with *A. indica* extract was significantly higher at all doses, in comparison to the infected untreated group (*P* < 0.01), and was comparable (non-significantly different [41]) to the values observed in the infected groups treated with chloroquine or artemether, and to uninfected group values, which were also significantly different from infected untreated group values (*P* < 0.01 for all three groups).

**Extract effect on caspase 3 expression**

The effect of *A. indica* on the expression of caspase 3 in pyramidal neurons of *P. berghei*-infected mice is shown in Figure 2. Pyramidal neurons of mice treated with *A. indica* extract displayed a significant decrease in caspase 3 expression at the highest dose, in comparison to the infected untreated group (*P* < 0.05), comparable to the decreases induced by chloroquine (*P* < 0.05 vs infected untreated group) or artemether (*P* < 0.05 vs infected untreated group).

**Extract effect on Fas and Fas ligand expression**

The effect of *A. indica* on Fas and Fas ligand expression in *P. berghei*-infected mice pyramidal neurons is shown in Figure 3. Pyramidal neurons of mice treated with *A. indica* extract displayed a significant decrease in Fas expression at the highest dose, in comparison to the infected untreated group (*P* < 0.05) and a decrease in Fas ligand expression at doses 500 and 1000 mg/kg (*P* < 0.05 vs infected untreated group). The significant decreases observed were comparable to those induced by chloroquine (*P* < 0.05 for Fas and *P* < 0.01 for Fas ligand vs infected untreated group) or artemether (*P* < 0.05 for Fas and *P* < 0.01 for Fas ligand vs infected untreated group).

**Extract effect on TNF expression**

The effect of *A. indica* on TNF expression in pyramidal neurons of *P. berghei*-infected mice is shown in Figure 4.

---

**Figure 4 TNF expression.** A. Micrographs showing the expression of tumor necrosis factor (TNF) in pyramidal neurons of representative examples of (from left): an uninfected mouse, an untreated Plasmodium berghei-infected mouse (inf.), and a *P. berghei*-infected mouse treated with Azadirachta indica crude extract. B. Effect of *A. indica* on the expression of TNF in pyramidal neurons of *P. berghei*-infected mice. Note the significant decrease in expression following treatment with chloroquine (chior.), artemether (artem.), or any of the doses of *A. indica* extract used.
Pyramidal neurons of mice treated with A. indica extract displayed a significant decrease in TNF expression at all doses used, in comparison to the infected untreated group (P < 0.01 at 1000 mg/kg). This effect was comparable to the decrease in TNF expression induced by chloroquine (P < 0.01 vs. infected untreated group) or artemether (P < 0.05 vs. infected untreated group).

**Extract effect on NOS expression**

The effect of A. indica on the expression of NOS in P. berghei-infected mice pyramidal neuron is shown in Figure 5. Azadirachta indica extract induced a significant decrease in NOS expression, in comparison to the infected untreated group. However, such decrease was statistically significant and comparable to the effect of chloroquine (P < 0.05 vs. infected untreated group) or artemether (P < 0.05 vs. infected untreated group) only at the highest dose used (1000 mg/kg, P < 0.05).

**Extract effect on brain oedema severity**

The effect of A. indica extract on brain oedema severity in P. berghei-infected mice is shown in Figure 6. Azadirachta indica extract induced a significant decrease in brain oedema severity at all doses used, in comparison to the infected untreated group (P < 0.05), which was comparable to the effect of chloroquine (P < 0.01 vs. infected untreated group) or artemether (P < 0.05 vs. infected untreated group).

**Discussion**

The present study points out the protective effects of A. indica extract on pyramidal neurons in experimental cerebral malaria induced by P. berghei-infection in mice.

**Protective effects on pyramidal neurons**

Pyramidal neuron density study revealed comparable values between P. berghei-infected mice treated with the extract of A. indica and uninfected mice, which were significantly different from untreated P. berghei-infected mice (disease control group) where a significant decrease in pyramidal neuron density, characteristic of cerebral malaria insult [14,18-20], was observed. These findings suggest that the extract protected pyramidal neurons from cerebral malaria-induced apoptosis. In order to further characterize these effects, the expression of apoptosis markers was studied, considering the importance of this phenomenon in cerebral malaria-associated encephalopathy [7-9].

---

**Figure 5 NOS expression.** A. Micrographs showing the expression of nitric oxide synthase (NOS) in pyramidal neurons of representative examples of (from left): an uninfected mouse, an untreated Plasmodium berghei-infected mouse (inf.), and a P. berghei-infected mouse treated with Azadirachta indica crude extract. B. Effect of A. indica on the expression of NOS in pyramidal neurons of P. berghei-infected mice. Note the significant decrease in expression following treatment with chloroquine, artemether, and A. indica extract highest dose. Data are mean ± SEM.
Striking decrease in the expression of apoptosis markers

The markers of apoptosis studied were caspase 3, Fas, and Fas ligand, which are commonly used for the detection of apoptosis in neuronal populations [13,19]. Azadirachta indica extract induced a striking decrease in caspase 3, Fas, and Fas ligand expressions on pyramidal neurons of P. berghei-infected mice, particularly at the highest dose used. Considering that these markers are associated with the risk for neuron apoptosis [13,19], the present finding indicates that A. indica extract has anti-apoptotic effects on pyramidal neurons in experimental cerebral malaria. The latter effects probably account for at least part of the protective effects of the extract against pyramidal neuron death in treated P. berghei-infected mice.

Considering that the pro-inflammatory environment, and particularly infiltrating immune cells, contribute to the detrimental effects of cerebral malaria on neurons, including apoptosis in sensible neuronal populations [12,14,42], through extrinsic mediators of apoptosis such as TNF and NOS [12,43,44], we have addressed the effect of A. indica extract on these inflammatory triggers of apoptosis in P. berghei-infected mice.

Mitigation of neuroinflammatory triggers of apoptosis and brain oedema severity

Treatment with A. indica extract induced decreases in pyramidal neuron expression of TNF and NOS in P. berghei-infected mice as compared with disease control group,
suggesting that the extract modulated inflammation in the brain parenchyma. Besides, considering that brain oedema is a major causative of the inflammatory response in the brain parenchyma (through infiltrating danger or pathogen-associated molecules [10,11]), the decrease in oedema severity observed in groups treated with the extract in the present study, indicate that the aforementioned anti-inflammatory effects may be mediated, at least in part, by protective effects on brain vessels. These findings are in agreement with our precedent observations in Purkinje cells of P. berghei-infected mice, where A. indica also displayed neuroprotective effects [16]. Comparable effects of A. indica extract have been reported in other models of detrimental neuroinflammation associated with brain oedema, including cerebral post-ischemic reperfusion and hypoperfusion in rats [45,46]. Thus, the findings herein reported confirm that A. indica extract has neuroprotective effects in experimental cerebral malaria, and indicate that such effect may be mediated through protective effects on brain vessels and the consequent decrease in neuroinflammation severity. Not surprisingly and interestingly, chloroquine and artemether, drugs in use for cerebral malaria treatment in the field [37,47], also induced similar effects, corroborating their beneficial effects reported in humans, and pointing out at least part of the mechanisms accounting for these effects. It appears, therefore, that future studies aiming at unraveling the active principle(s) accounting for the beneficial effects of A. indica extract reported may provide key elements for the development of new drugs for cerebral malaria. Subjecting the bioactive agents of Azadirachta indica which have already been characterized, such as gedunin [33, 48], to a similar study may provide better insights into the neuroprotective effects herein described.

Conclusions

Azadirachta indica extract did not protect infected mice from death from cerebral malaria, although the highest doses slightly delayed death time. However, A. indica extract displayed neuroprotective effects mediated probably by mitigating oedema build up, and modulating both neuroinflammatory triggers of apoptosis and apoptosis signaling pathways. The use of extracts of A. indica in African and Asian folk medicine and practices for the treatment of malaria and cerebral malaria is justified. Characterization of the active principle(s) accounting for these effects will probably provide new drugs, which are particularly needed in the current context of increased chemoresistance to chloroquine.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MF, EAK, SAK, MAA, AM, PFSE, and YHA participated in the preparation of the manuscript. MF and PFSE analysed the data, prepared the figures, and were in charge of the manuscript submission. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to acknowledge the Qassim University and Ministry of Higher education for funding this project as well as Dr. C. R. Pillai, National Malaria Institute, New Delhi, India for donation of the parasite. The authors would like to acknowledge the critical thinking and brainstorming of Professor Mustafa Idris. The authors would like to acknowledge the help of Dr. Imran Ulhag for providing a second opinion in analyzing the immunohistochemistry results; the technical support of Ali Yousif, Mohammed Awad and Said Youssif in the study and the help of Dr. Mohsin Shaik and Dr. Mdgy Abdelislam in the statistical analysis. Special thanks are due to the Institute of Endemic Diseases of the University of Khartoum and to the College of Applied Medical Sciences of Qassim University for the logistic support, and to Prof. Bunyamin Shahnin for his insightful suggestions.

Author details

1Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. 2Department of Pharmacognosy, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan. 3Department of Laboratory Medicine, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia. 4Department of Optometry, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia. 5Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.

Received: 1 February 2013 Accepted: 20 August 2013

References

1. Mishra SK, Newton CR: Diagnosis and management of the neurological complications of falciparum malaria. Nat Rev Neurol 2009, 5:189–198.
2. Idro R, Marsh K, John CC, Newton CR: Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res 2010, 68:267–274.
3. Idro R, Ndiritu M, Ogutu B, Mithwani S, Maitland K, Berkley J, C ESV, Fegan G, Bauni E, Peshu N, Marsh K, Neville B, Newton C: Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA 2007, 297:2232–2240.
4. Khara M, Carter JA, Holding PA, Varga-Khadem F, Scott RC, Idro R, Fegan GW, de Haan M, Neville BG, Newton CR: Impaired everyday memory associated with encephalopathy of severe malaria: the role of seizures and hippocampal damage. Mol J 2009, 8:273.
5. Kanuki M, Ikumi M, Ojji J, Sadasangani M, Idro R, Olfuro A, Bejon P, Berkley JA, Marsh K, Newton CR: Acute seizures attributable to falciparum malaria in an endemic area on the Kenyan coast. Brain 2011, 134:i151–1528.
6. Gwer S, Thuo N, Idro R, Ndiritu M, Boga M, Newton C, Kirkham F: Changing trends in incidence and aetiology of childhood acute non-traumatic coma over a period of changing malaria transmission in rural coastal Kenya: a retrospective analysis. BMJ Open 2012, 2:e000475.
7. Kaiser K, Tesier A, Ferrandiz J, Bugu E, Meiller A, Latour C, Peyron F, Cesupoglu P, Picot S: Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J Infect Dis 2006, 193:987–995.
8. Combes V, Cotel N, Faisse D, Wassmer SC, Grau GE: Cerebral malaria: role of microparticles and platelets in alterations of the blood–brain barrier. Int J Parasitol 2006, 36:541–546.
9. Faisse D, El-Assaad F, Alessi MC, Fusai T, Combes V, Grau GE: Platelet-endothelial cell interactions in cerebral malaria: the end of a cordial understanding. Thromb Haemost 2005, 94:336–340.
10. Pino P, Taoufiq Z, Nitchue J, Voulodoukis I, Mazier D: Blood–brain barrier breakdown during cerebral malaria: suicide or murder? Thromb Haemost 2005, 94:336–340.
11. Bisser S, ON O-M-O-B, Toure FS, Taoufiq Z, Bouteille B, Bugu E, Mazier D: Harbouroing in the brain: a focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis. Int J Parasitol 2006, 36:529–540.
12. Lovegrove FE, Gharib SA, Patel SN, Hawkes CA, Kain KC, Liles WC: Expression microarray analysis implicates apoptosis and interferon-

Page 8 of 9
Bedri et al. Malaria Journal 2013, 12:298
http://www.malariajournal.com/content/12/1/298
responsive mechanisms in susceptibility to experimental cerebral malaria, Am J Pathol 2007, 171:1894–1903.

13. Lackner P, Burger C, Pfaller K, Heussler V, Helbok R, Morandell M, Breussner G, Tannich E, Schmutzhard E, Beer R: Apoptosis in experimental cerebral malaria: spatial profile of cleaved caspase-3 and ultrastructural alterations in different disease stages. Neuropathol Appl Neurobiol 2007, 33:500–571.

14. Toure FS, Oueue-Missi-Oukem-Boyer O, Bisigou U, Moussa O, Rogier C, Pino P, Master D, Bissi S: Apoptosis: a potential triggering mechanism of neurological manifestation in Plasmodium falciparum malaria. Parasite Immunol 2008, 30:47–51.

15. Teo JT, Swayney OB, Silber E: Cerebellar ataxia after malaria. Neurology 2009, 73:73–74.

16. Farahna M, Bedri S, Khalid S, Idri M, Pillai CR, Khalil EA: Anti-plasmodial effects of Azadirachta indica in experimental cerebral malaria: Apoptosis of cerebellar Purkinje cells of mice as a marker. N Am J Med Sci 2010, 2518–525.

17. Duque V, Seixas D, Ventura C, Da CS, Melco-Silvestre A: Plasmodium falciparum malaria, bilateral sixth cranial nerve palsy and delayed cerebellar ataxia. J InfectDev Cires 2012, 6:590–294.

18. Potter S, Chan-Ling T, Ball HJ, Mansour H, Mitchell A, Pillai CR, Khalil EA: Anti-plasmodial activity of selected drugs in southeast Asia and sub-Saharan Africa. J Ethnopharmacol 2011, 111:285–295.

19. Highley JR, Walker MA, McDonald B, Crow TJ, Esiri MW: Size of hippocampal pyramidal neurons in schizophrenia. Br J Psychiatry 2003, 183:414–417.

20. Bairol R, Rahman SF, Hasiballah K, Chong W, Talib H, Yamin J, Jabbarzade M, Tie T, Othman F, Moklas M, Abdullah W, Ahmad Z: Plasmodium berghei ANKA infection in ICR mice as a model of cerebral malaria. Iran J Parasitol 2012, 7:62–74.

21. Lekic T, Rolland W, Manenoik A, Kraft PR, Kampfer JE, Suzuki H, Hartman RE, Tang J, Zhang JH: Evaluation of the hematoma consequences, neurobehavioral profiles, and histopathology in a rat model of pontine hemorrhage. J Neurosurg 2013, 118:465–477.

22. Sprent A, Beller D: When can ‘non significantly different’ treatments be considered ‘equivalent?’ Br J Clin Pharmacol 1979, 6:253–624.

23. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, Potter S, Medana IM, Miu J, Ball HJ: Immunopathogenesis of cerebral malaria. Int J Parasitol 2006, 36:569–582.

24. Alvarez S, Blanco A, Fresno M, Munoz-Fernandez MA: TNF-alpha contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT. PLoS One 2011, 6:e16100.

25. Bienvenu AL, Gonzalez-Rey E, Picot S: Apoptosis induced by parasitic diseases. Parasit Vectors 2010, 3:106.

26. Yannapelviar S, Rai S, Kumar M, Chauhan S, Acharya SB: Neuroprotective effect of Azadirachta indica on cerebral post-ischemic reperfusion and hypoperfusion in rats. Life Sci 2005, 76:1325–1338.

27. Vanlitha V, Subrata P, Kshetrimayum B, Toppan D, Ramakrishnan C, Sahu BB, Kaur H, Angus B, Stepniewska K, Guerin PJ, Fernandez FM: Hostetler DM, Swamidoss I, Harris GA, Powell K, Timmermans AE, Amin AA, Lackner P: Altered brain ultrastructure and use by pastoral and agro-pastoral communities in Erer Valley of Babile Wereda, Eastern Ethiopia. J Ethnobiol Ethnomed 2013, 9:14.

28. Bari S, Gharab S, Al Kalbani A, Al Kindi M: Apoptosis induction and protein expression in cerebral malaria in mice. Biomed Res Int 2012, 2012:407–416.

29. Lackner P, Burger C, Pfaller K, Heussler V, Helbok R, Morandell M, Breussner G, Tannich E, Schmutzhard E, Beer R: Apoptosis in experimental cerebral malaria: spatial profile of cleaved caspase-3 and ultrastructural alterations in different disease stages. Neuropathol Appl Neurobiol 2007, 39:307–371.

30. Toure FS, Oueue-Missi-Oukem-Boyer O, Bisigou U, Moussa O, Rogier C, Pino P, Master D, Bissi S: Apoptosis: a potential triggering mechanism of neurological manifestation in Plasmodium falciparum malaria. Parasite Immunol 2008, 30:47–51.

31. Bedri et al. Malaria Journal 2013, 12:298

http://www.malariajournal.com/content/12/1/298

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit
doi:10.1186/1475-2875-12-298
Cite this article as: Bedri et al.: Azadirachta indica ethanolic extract protects neurons from apoptosis and mitigates brain swelling in experimental cerebral malaria. Malaria Journal 2013 12:298.